Northwest Biotherapeutics | NWBO - Des Atouts





Des Atouts Changement Date
Agenus USD 172.69M 13.76M 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Celldex Therapeutics USD 782.35M 271.09M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Merck USD 129.8B 1.12B 2026-06
Northwest Biotherapeutics USD 80.05M 49.44M 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Plus Therapeutics USD 14.03M 5.89M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06